這是一項第三期、隨機、雙盲、安慰劑對照、多中心研究，評估 durvalumab 對比安慰劑作為鞏固治療，用於局部晚期、不可切除的非小細胞肺癌（第三期）患者，這些患者在接受確定性鉑類化放療後未出現疾病惡化。

適應症：Carcinoma, Non-Small-Cell Lung

收案條件

Age≥18 years
Documented NSCLC and present with locally advanced, unresectable (Stage III) disease;
Receipt of concurrent or sequential chemoradiation therapy,
No progression following definitive, platinum-based, concurrent or sequential chemoradiation therapy
World Health Organization (WHO) PS of 0 or 1;
No prior exposure to any anti CTLA-4, anti-PD-1, anti-PD-L1, or anti PD L2 antibodies, excluding therapeutic anticancer vaccines
Adequate organ and marrow function required
Life expectancy of at least 12 weeks
Tumor PD-L1 status, with the Ventana SP263 PD-L1 IHC assay determined by a reference laboratory, must be known prior to randomization.
Tumour sample requirements are as follows: Provision of a tumour tissue sample (newly acquired sample \<=3 months old is preferred, but an archived sample \<=6 months old is acceptable) in a quantity sufficient to allow for analysis.

History of allogeneic organ transplantation, or another primary malignancy, or active primary immunodeficiency.
Active or prior documented autoimmune or inflammatory disorders
Uncontrolled intercurrent illness that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the patient to give written informed consent
Active infection including tuberculosis hepatitis B hepatitis C (HCV), or human immunodeficiency virus (positive human immunodeficiency virus \[HIV\] 1/2 antibodies).
Mixed small cell and NSCLC histology, sarcomatoid variant
Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 from the prior chemoradiation therapy.
Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.
Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

Durvalumab 作為非小細胞肺癌患者鞏固治療的研究